As a leading CRO of antibody generation and development, Creative Biolabs offers application-specific antibody development services to global clients. With experienced scientists and advanced technology, we have established a series of high-quality in vitro diagnostic (IVD) antibody development services against biomarkers of different diseases. Here, we introduce our IVD antibody development services for CD64 marker.
CD64
CD64 is an IgG Fc fragment receptor 1 (FcγRI) capable of recognizing immunoglobulins, having a high affinity for IgG monomers, mediating humoral and cellular immunity, and having an early diagnostic value for infectious diseases. It is a transmembrane glycoprotein with a relative molecular weight of 72 kD. It is encoded by three genes, A, B, and C located on the long arm of chromosome 1, and is a member of the immunoglobulin superfamily. The basic structure of CD64 is divided into extracellular portions, transmembrane segments and cytoplasmic tails. Normally, CD64 is mainly expressed on the surface of macrophages, monocytes, and dendritic cells, and it is rarely expressed on the surface of neutrophils. It achieves clearance of pathogenic microorganisms mainly through antibody-dependent cytotoxicity, phagocytosis and clearance of immune complexes. A large number of pro-inflammatory cytokines (gamma interferon and neutrophil colony-stimulating factor) release and neutrophils are activated when the organism infects or endotoxin invades, and CD64 is stimulated by γ interferon and neutrophil colony-stimulating factor expression. Under normal circumstances, CD64 can be elevated 4 to 6 hours after the infection or endotoxin invasion.
CD64 as Marker of Sepsis
CD64 is a FcγRI that recognizes immune proteins, mediates humoral and cellular immunity. When the body is infected, it is stimulated by factors such as lipopolysaccharide (LPS), granulocyte colony-stimulating factor (G-CSF) and C-interferon (IFN-C). The expression of CD64 increases on the surface of neutrophils. Studies have shown that the level of CD64 expression in peripheral blood neutrophils in patients with sepsis is significantly higher than normal, indicating that peripheral blood neutrophil CD64 expression levels are closely related to sepsis. The level of CD64 expression in the severe sepsis group was higher than that in the general sepsis group and the pneumonia group, indicating that CD64 was positively correlated with the degree of infection. The expression of CD64 in disseminated intravascular coagulation (DIC) caused by infection is significantly higher, and the degree of increase is related to the severity of infection and survival rate and can be used as an indicator of prognosis of infectious DIC.
Fig.1 CD64 can be detected as a biomarker of sepsis.1
IVD Antibody Development Services Targeting CD64 Marker
Under normal conditions, CD64 is mainly expressed on the surface of monocytes, macrophages, and dendritic cells, with little expression of neutrophils on the surface. When the body suffers from infectious diseases, the expression of CD64 on the surface of neutrophils rises rapidly, and CD64 has higher sensitivity and specificity in the diagnosis of infectious diseases. Therefore, CD64 can be used as a target for monitoring the disease. Creative Biolabs offers anti-CD64 antibody development services for the use of diagnostic of sepsis. Having completed a number of IVD antibody generation and development projects, Creative Biolabs is confident to offer you the best products and services to promote your project a success.
If you are interested in the services we can provide, please don't hesitate to contact us or directly send us an inquiry. We will get in touch with you as soon as possible.
Reference
For Research Use Only.
